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Abstract: Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca
2+ permeant non-selective cation channel expressed in 
a subpopulation of primary afferent neurons. TRPV1 is activated by physical and chemical stimuli. It is critical for the de-
tection of nociceptive and thermal inflammatory pain as revealed by the deletion of the TRPV1 gene. TRPV1 is distrib-
uted in the peripheral and central terminals of the sensory neurons and plays a role in initiating action potentials at the 
nerve terminals and modulating neurotransmitter release at the first sensory synapse, respectively. Distribution of TRPV1 
in the nerve terminals innervating blood vessels and in parts of the CNS that are not subjected to temperature range that is 
required to activate TRPV1 suggests a role beyond a noxious thermal sensor. Presently, TRPV1 is being considered as a 
target for analgesics through evaluation of different antagonists. Here, we will discuss the distribution and the functions of 
TRPV1, potential use of its agonists and antagonists as analgesics and highlight the functions that are not related to noci-
ceptive transmission that might lead to adverse effects.  
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INTRODUCTION 
  Pain is manifested as nociceptive (noxious stimuli), in-
flammatory (tissue damage) and neuropathic (neuronal le-
sion) pain. Noxious stimuli are transduced by peripheral no-
ciceptors, which transmit nociceptive information to pain 
processing areas in the brain via the spinal cord. Sensory 
nerve endings express chemo-, mechano-, and thermo-sensi-
tive ion channels, which include acid sensitive ion channels 
(ASIC), degenerin/epithelial sodium channels (DEG/ENAC), 
adenosine triphosphate (ATP) gated ion channels (P2X), and 
transient receptor potential (TRP) channels [28, 49, 116, 
170]. TRP channels (TRPVanilloid, TRPAnkyrin, TRPClas-
sical,andTRPMelastatin)arechemo-, mechano-, and thermo-
sensitive [60, 123]. These receptors are sensitized by proin-
flammatory agents, the receptors of which are coupled to 
intracellular signaling pathways and mediate heightened pain 
perception.  
 TRPV1isa transducer of noxious temperature and chemi-
cal stimuli [31]. It can initiate nociceptive signaling by gen-
erating a receptor potential at the peripheral nerve endings by 
increasing membrane permeability to monovalent and diva-
lent cations including Ca
2+. TRPV1 is sensitized by inflam-
matory mediators and is responsible, in part for inflamma-
tory pain arising from tissue injury [65, 76, 86]. TRPV1 ex-
pression is increased in neuropathic pain resulting from 
nerve lesion [55, 72]. Retrograde transport of nerve growth 
factor (NGF) released at the site of peripheral tissue injury to 
the DRG soma results in activation of p38 mitogen-activated 
protein kinase (p38 MAPK) [76]. Enhanced translation and 
transport of the TRPV1 protein selectively to the peripheral 
terminals of sensory neurons is suggested to underlie thermal 
hypersensitivity following tissue injury [76]. This is gener-
ally referred to as peripheral sensitization, although in-
creased expression of TRPV1 at the central terminals of 
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DRG neurons could contribute to central sensitization. We 
have recently demonstrated that PKC-mediated phosphoryla-
tion of TRPV1, expressed on the central terminals of sensory 
neurons, activates the receptor at body temperature resulting 
in enhanced glutamatergic synaptic transmission [162]. In-
creased neuronal activity in primary afferents could augment 
the activity of second order dorsal horn neurons and third 
order thalamic neurons. This in turn, may be interpreted as 
heightened pain by cortical pain sensing areas. The finding 
that TRPV1 knock-out mice are less susceptible to certain 
modalities of pain, suggests the possibility of TRPV1 an-
tagonists as the next generation of analgesics. The selectivity 
of TRPV1 as a target is bolstered by the reports that TRPV1 
knock-out or ablation of TRPV1 containing neurons by neo-
natal administration of capsaicin or resiniferatoxin (RTX) 
does not exhibit other obvious abnormalities [30, 135, 175]. 
However, it is yet to be determined how the block of TRPV1 
will impact in a preexisting disease state.  
DISTRIBUTION OF TRPV1 
Peripheral Nervous System 
  A subset of primary sensory neurons with soma in dorsal 
root ganglia (DRG), trigeminal ganglia (TG) and nodose 
ganglia expresse TRPV1 [31, 67]. These are peptidergic, 
small to medium diameter neurons that give rise to un-myeli-
nated C-fibers and thinly myelinated A-fibers. TRPV1 is 
also expressed in neurons that are labeled for  -D-galactosyl-
binding lectin IB4 and express the ionotropic ATP receptor 
P2X3 [67, 68]. In inflammatory conditions, capsaicin insensi-
tive neurons can express TRPV1 [8, 9]. Tissue or nerve in-
jury may also change the expression of neurotransmitter re-
ceptors and signaling molecules in nociceptors, which may 
underlie chronic pain conditions [199]. Central terminals of 
vanilloid-sensitive neurons form synapses on the dorsal horn 
of the spinal cord (DRG neurons) or the spinal nucleus of the 
trigeminal tract (TG neurons) [105, 106, 107] transmitting 
nociceptive information to the CNS.  
  TRPV1 expression has been established in non-neuronal 
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cells [194], uroepithelial cells [21, 22] and keratinocytes [47, 
75, 166]. The role of TRPV1 in different regions of the body 
is briefly discussed below. 
Central Nervous System 
  Expression of TRPV1 in various regions of the brain has 
been successfully established using an array of techniques 
including RT-PCR, in situ hybridization and [
3H]-RTX bind-
ing [2, 31, 99, 100, 119, 147, 172, 184]. Application of cap-
saicin resulted in an increase in the excitatory glutamatergic 
synaptic transmission in the nucleus tractus solitarius (NTS) 
[52], locus coeruleus [111], dopaminergic neurons of the 
substantia nigra [110] and the preoptic hypothalamic neurons 
[85]. In these experiments, the facilitatory effects of cap-
saicin on the transmission are due to activation of presynap-
tic TRPV1 receptors resulting in enhanced glutamate release. 
However, acute capsaicin application has also been reported 
to produce postsynaptic effects in NTS slice preparations 
[52], suggesting the expression of TRPV1 in second order 
neurons. TRPV1 activation in cortical slices also results in 
glutamate release [151]. In addition, iontophoretic applica-
tion of capsaicin in the periaqueductal gray produced analge-
sia, which was inhibited by NMDA receptor blockers [132]. 
Interestingly, in another study, low concentrations (10 nM) 
of capsaicin resulted in hyperalgesia, as indicated by in-
creased neuronal activity in the ventral medulla and de-
creased latency of nocifensive behavior [115]. Furthermore, 
peripheral application of capsaicin enhanced bursting activ-
ity in the dorsal raphe nucleus, enhanced firing rate and 
bursting activity of dopaminergic neurons when applied to 
ventral tegmental area [109], but inhibited neuronal spike 
activity in the cerebellum [150]. Activation of medial tha-
lamic neurons by capsaicin enhanced the firing frequency of 
these neurons, which was inhibited by morphine [11].  
  TRPV1 expression has been demonstrated in the basal 
ganglia by enhanced locomotion, vasodilation and hypo-
thermia induced by capsaicin injection [43, 44]. The physio-
logical functions of TRPV1 in the hippocampus are unclear 
[7, 93]. TRPV1 activation by its agonists capsaicin, RTX and 
anandamide in the CA1 region of hippocampal slices re-
sulted in the facilitation of paired pulse depression of spike 
potentials [7]. The enhancement of inhibitory synaptic 
transmission is suggested to result from the influx of Ca
2+
through TRPV1, expressed on the presynaptic terminals of 
GABAergic neurons. However, this could not be demon-
strated in ex-vivo assays performed to study the effects of 
TRPV1 activation on K
+-evoked Ca
2+ entry and release of 
radiolabeled GABA from rat hippocampal nerve terminals 
[7]. Recently, it has been demonstrated that TRPV1 knock-
out mice show reduced anxiety-related behavior [112]. These 
animals also exhibited less freezing following auditory fear 
conditioning and stress sensitization as compared to their 
wild type littermates [112]. In addition, the knock-out mice 
demonstrated deficits in developing long-term potentiation in 
the Schaffer collateral-commissural pathway stimulation, 
which may underlie reduced fear and anxiety behavior [112].  
  Intraperitoneal administration of capsaicin and endocan-
nabinoid uptake inhibitor AM404 produced a drop in body 
temperature. Pre-administration of capsazepine but not can-
nabinoid receptor antagonist inhibited the hypothermic ef-
fects of both capsaicin and AM404, underscoring the impor-
tance of TRPV1 in regulating body temperature [142]. Fur-
thermore, elevated body temperature has been reported in 
capsaicin-desensitized animals as compared to control or 
TRPV1
-/- mice [177]. Capsaicin-desensitized animals have 
been previously reported to exhibit hyperthermia in response 
to systemic administration of the E. coli endotoxin, lipopoly-
saccharide (LPS) [176]. In contrast to these findings, Iida 
and colleagues [74] reported normal body temperature regu-
lation in TRPV1
-/- mice and hypothermia in response to sys-
temic LPS administration, suggesting a role of TRPV1 in 
temperature regulation at a peripheral site. Recently, an in-
teresting  in vivo study evaluating the efficacy of various 
TRPV1 antagonists in clinical development reported that 
antagonism of the TRPV1 receptor resulted in hyperthermia 
[56]. Lipophilic TRPV1 antagonists that crossed the blood-
brain barrier as well as peripherally acting antagonists in-
duced comparable hyperthermia suggesting that TRPV1 is 
tonically activated and involved in regulating body tempera-
ture at sites mainly in the periphery [56]. Thus, the exact 
mechanisms involving TRPV1 in body temperature regula-
tion need to be further examined and hence caution should 
be exercised designing and testing TRPV1 antagonists.  
Cardiovascular System 
  The heart is richly innervated by sensory and vagal nerve 
endings. These nerves transduce chemical and mechanical 
changes from the heart to the brain. Sensory nerve endings 
supplying the heart express TRPV1 [202] and are able to 
release vasoactive peptides like CGRP and SP upon activa-
tion. The endogenous activator of TRPV1 in the heart are 
possibly protons, as lactic acid is produced during ischemia. 
Lactic acidosis and extracellular acidification are important 
in inducing depolarization during cardiogenic sympthoexci-
tatory reflex (CSR) [17, 116, 134, 153, 170]. Ablation of 
TRPV1-expressing afferent nerve endings by RTX admini-
stration has been reported to abolish CSR mediated cardiac 
pain [202]. Furthermore, reactive oxygen and nitrogen spe-
cies (ROS and RNS) liberated during myocardial infarction 
and reperfusion could activate TRPV1 present on the sensory 
nerve endings [154, 155]. 5-Lipoxygenase (5-LOX) metabo-
lites of arachidonic acid have been shown to activate cardiac 
sensory afferents possibly by activating TRPV1 during myo-
cardial ischemia [169].  
  Vasoactive peptides modulate cardiac functions in a 
complex manner. Capsaicin-induced neuropeptide release 
may induce vasodilatation, enhance cardiac blood flow and 
facilitate recovery from ischemia [188]. On the contrary, it 
has been suggested that generation of arachidonic acid me-
tabolite, 20-hydroxyeicosatetraenoic acid (20-HETE) results 
in vasoconstriction via the activation of TRPV1. Destruction 
of c-fiber nerve endings by capsaicin, antagonism of TRPV1 
using capsazepine, ruthenium red or inhibiting substance P 
(SP) receptor by its antagonist have been shown to prevent 
myogenic constriction [156].  
Respiratory System 
  The expression of TRPV1 in the sensory nerve endings 
arising from the nodose ganglia is well established [119]. 
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pathogenesis of diseases, such as asthma and chronic ob-
structive pulmonary disease. TRPV1 agonists induce bron-
choconstriction and airway hyperactivity, enhance mucous 
secretionand induce microvascular exudation [58, 88]. These 
effects are mediated in part by SP and calcitonin gene related 
peptide (CGRP) released from the nerve terminals upon 
TRPV1 activation. Furthermore, sensitization of TRPV1 by 
inflammatory mediators like prostaglandins (PGs) [108, 
125], bradykinin (BK) [35, 138, 139], nerve growth factor 
(NGF) [35, 76, 161] and LOX metabolites of arachidonic 
acid [71, 73] may lead to exacerbation of asthma. Studies 
have shown that the sensitivity of capsaicin-induced cough 
reflex/response is heightened in chronic airway inflamma-
tory diseases [58]. TRPV1 is also shown to be involved in 
citric acid-induced cough [95, 186], gastroeosphageal reflux-
induced asthma as well as airway disorders induced follow-
ing inhalation of acid fog or pollutants [62, 65, 95]. Thus, 
selective TRPV1 antagonists may prove promising in treat-
ing many inflammatory airway disorders. 
Urinary Bladder 
  TRPV1 in the urinary system is associated with percep-
tion of pain and regulating the micturition reflex. Its expres-
sion in the urinary bladder, ureter, urethra and renal pelvis of 
rats has been established by using [
3H] RTX and immunohis-
tochemistry [1, 13, 21, 99, 135, 174, 182]. TRPV1 has been 
reported to co-localize with CGRP, and SP receptors in the 
rat urinary bladder [13, 14, 41]. 
  TRPV1 plays an important role in enhancing bladder 
reflex contractions in the chronically inflamed bladder [27, 
37, 48, 98] and its responses can be significantly potentiated 
by the activation of PKC [157]. Application of capsazepine 
resulted in decreased contractions in the bladder inflamed by 
cyclophosphamide [48]. Furthermore, in acetic acid or 
lipopolysaccharide (LPS)-induced inflammation of the blad-
der, the frequency of urinary bladder contractions was sig-
nificantly enhanced in wild type TRPV1 mice but not in 
TRPV1 knock-out mice. The frequency of bladder reflex 
contractions were reported to be similar in both TRPV1
+/+
and TRPV1
-/- mice and it was shown that high concentra-
tions of capsazepine had no effect on the bladder reflex ac-
tivity of normal bladders [48]. In contrast to these results, 
Birder and colleagues [21] reported that TRPV1
-/- mice ex-
hibited high frequencies of non-voiding contractions, in-
creased bladder volume and enhanced the frequency of low-
volume urinations, suggesting that TRPV1 is involved in 
normal bladder functions. Conflicting data from different 
groups suggest that TRPV1 plays an important yet complex 
role in regulating bladder function.  
   Intravesical administration of capsaicin and RTX, a po-
tent TRPV1 agonist results in a marked decrease in TRPV1, 
SP and CGRP immunoreactivity in the rat urinary bladder 
[13, 14], which may be as a result of nerve terminal degen-
eration mediated by these agents [27, 35, 37, 40, 146, 163]. 
This is the underlying mechanism for the successful demon-
stration of TRPV1 agonists in treating interstitial cystitis [99] 
and urinary bladder hyperreflexia [37, 45, 46]. In this regard, 
therapeutic potential of RTX in treating urinary incontinence 
is superior to capsaicin [97, 98]. Capsaicin administration is 
associated with rapid depolarization of the pain transmitting 
c-fibers, which is perceived as a burning pain. However, 
RTX slowly depolarizes the c-fibers resulting in depolariza-
tion block leading to minimal pain during administration 
[140]. Unfortunately, the high lipophilicity of RTX poses 
problems with efficient packaging and loss of potency after 
reconstitution. RTX is in clinical trials for treating urinary 
bladder hyperreflexia.  
Gastrointestinal Tract 
  TRPV1 immunoreactivity has been observed in the vis-
ceral sensory afferents and on the vagal afferents that supply 
the stomach mucosa, musculature and enteric plexuses [10, 
136, 152, 165, 197]. Visceral sensory neurons express CGRP 
and SP [59, 67, 148, 197]. Capsaicin-sensitive neurons in the 
gut serve both afferent and efferent functions [66, 105]. 
Transmission of gastric pain sensation to the higher centers 
of the brain constitutes their afferent function, whereas re-
lease of CGRP and SP in the periphery reflects their efferent 
function. Neurons of nodose ganglion contain high levels of 
TRPV1 and 70% of the vagal afferents are sensory in nature 
[120].  
  TRPV1 activation in the foregut by capsaicin produces 
gastric hyperemia and enhances gastric protection by in-
creasing mucus and HCO3
- secretion [65, 69, 84, 86, 87, 180, 
181]. The protease-activated receptor 2 (PAR2), a Gq-
coupled receptor is suggested to sensitize TRPV1 by PKC 
activation in the stomach, enhancing gastric protection by 
increasing gastric mucus secretion. This effect is TRPV1 
specific as it was inhibited by capsazepine and suggested to 
occur as a result of CGRP and tachykinin release upon 
TRPV1 activation [86]. One of the major issues with con-
ventional COX 1 and 2 inhibiting non-steroidal anti-inflam-
matory agents is their ability to increase gastric acidity, lead-
ing to bleeding. However, this effect has been attributed to a 
lack of PG synthesis and action on their receptors (IP, EP2 
and EP3 in the duodenum and EP1 in the stomach) [12, 126, 
178], which causes an increase in the acid secretion. PGs do 
not directly induce nociception, but they are able to sensitize 
nociceptive ion channels to bring about pain perception. In 
this context, it is worth noting that the same sensitizing effect 
could play a role in the gastric mucosa. Application of cap-
saicin has been shown to increase HCO3
- secretion as effec-
tively as acid-induced HCO3
- secretion [6]. This effect could 
be specifically blocked by ablation of capsaicin sensitive 
neurons, capsazepine, a TRPV1 antagonist, indomethacin 
(COX 1 and 2 inhibitors) and N(G)-nitro-L-arginine meth-
ylester (L-NAME), a NO synthesis inhibitor. Capsaicin in-
creased mucosal PGI2 but not PGE2 levels, corroborating 
this observation that only PGI2 receptor knock-out mice 
abolished capsaicin induced HCO3
- secretion. Capsaicin-
induced HCO3
- secretion is contrary to the myth that food 
containing the hot chili pepper can worsen gastric acidity. 
One would expect an acid-induced effect to overlap that of a 
capsaicin-induced effect, given the ability of acid to activate 
TRPV1 potently. Interestingly, capsaicin-induced acid secre-
tion was blocked by capsazepine, L-NAME, indomethacin, 
in IP receptor knock-out mice and ablation of TRPV1 con-
taining neurons but not by the BK 2 receptor antagonist or 
the EP1 receptor antagonist [6]. However, the acid induced 
HCO3
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EP1 antagonist and sensory deafferentation but not by cap-
sazepine [6]. Thus, acid and capsaicin enhance HCO3
- secre-
tion through common players but likely through different 
receptors.  
  TRPV1 mediated CGRP release could play a role in in-
creasing blood supply to malignancies of the GI tract; the 
beneficial effect of COX inhibitors in this regard may arise 
from their ability to reduce TRPV1-mediated CGRP release 
and inhibition of PG-mediated angiogenesis. TRPV1 is asso-
ciated with inducing inflammation and tissue damage in the 
pancreas, ileum and colon following dextran sulphate so-
dium-induced colitis in rats [90, 91], caerulein-induced pan-
creatitis [129], Clostridium difficile toxin A- and endocan-
nabinoid-induced colitis [117, 118]. These effects of TRPV1 
are associated with release of SP from the sensory afferents 
that activates the neurokinin receptor resulting in an activa-
tion of immune cells, mast cells and enteric cells causing 
hypersecretion, inflammation and finally mucosal damage 
[65, 117]. Patients diagnosed with active inflammatory 
bowel disease demonstrate a greatly increased TRPV1 im-
munoreactivity in colonic nerve fibers [197, 201], suggesting 
an important implication of the TRPV1 antagonists in treat-
ing GI distress. Recently, it has been reported that TRPV1-
expressing pancreatic sensory neurons control islet inflam-
mation and insulin resistance in type I diabetes [143]. Abla-
tion of these TRPV1 positive sensory afferents by capsaicin 
application prevents the onset of diabetes and associated 
pancreatitis in diabetes prone non obese diabetic mice [143].  
Taste and Food Intake 
  A TRPV1 receptor variant is attributed to be the mam-
malian amiloride-insensitive non-specific salt taste receptor 
[103]. This receptor is expressed in fungiform taste receptor 
cells and is a non-selective cation channel, activated by va-
nilloids, temperatures >38˚C, inhibited by capsazepine and is 
absent in TRPV1 knock-out mice [103]. Thus, developing 
specific salt taste suppressors or enhancers may prove bene-
ficial in managing cardiovascular complications, such as 
hypertension. The activation of TRPV1 in the nodose ganglia 
by the endogenous feeding and body weight regulating lipid, 
oleoylethanolamide [3], resulted in visceral pain and reduced 
food intake in only wild type but not in TRPV1 knock-out 
mice [196]. Craving for spicy food may be as a result of cap-
saicin effect on the satiety centers [3]. It is interesting to note 
that the TRP channels that are purported to be involved in 
pain are also expressed in gustatory neurons and carry spe-
cific taste sensations. For example, TRPV1 carries the pun-
gent taste associated with capsaicin and vinegar, whereas 
TRPA1 carries the taste associated with mustard, horse rad-
ish and wasabi.  
Hearing 
  Capsaicin-mediated activation of the sensory nerves sup-
plying the cochlea has been reported to increase cochlear 
blood flow [191, 192 203]. This effect of capsaicin is attrib-
uted to the release of SP from the axons in the basilar artery, 
the anterior inferior cerebellar artery, the spiral modiolar 
artery, and the radiating arterioles of the cochlea [192]. 
TRPV1 immunoreactivity has been reported in the hair cells, 
organ of corti, vestibular and spiral ganglion cells of the 
cochlea[15, 203].5-LOXmetabolitesof AA activate TRPV1, 
TRPV1 and 5-LOX immunoreactivity has been observed in 
the neurons and satellite cells in adjacent sections of these 
ganglia [15]. TRPV1 activation in the cochlea is associated 
an increase in the threshold of auditory nerve compound 
action potentials and a reduced magnitude of cochlear mi-
crophonic and electrically-evoked otoacoustic emissions, 
suggesting an important modulatory role in the physiology of 
the inner ear [203]. In a recent study by Kitahara and col-
leagues [92], subcutaneous kanamycin administration in 
mice resulted in increased mRNA levels of TRPV1 as de-
termined by the real-time PCR technique in the spiral and 
vestibular ganglia. The authors concluded that upregulated 
TRPV1 in these ganglia may promote neuronal survival and 
underlie kanamycin-induced dizziness and tinnitus as side 
effects. Furthermore, TRPV1 may also be implicated in hear-
ing loss associated with inflammation in salicylates-induced 
tinnitus or in pathological conditions of the inner ear such as 
in Meniere’s disease or in migraines. Tinnitus can be equated 
to chronic pain conditions; both involve spontaneous neu-
ronal firing and likely to be mediated via TRPV1.  
Hair 
  Expression of TRPV1 on the hair follicle (mainly in the 
outer root sheath and hair matrix) has been established by 
using diaminobenzidine immunoreactivity [25]. Using cul-
tured human scalp hair follicles, capsaicin application was 
shown to inhibit hair shaft elongation and induce apoptosis, 
suppress proliferation and enhance premature hair follicle 
regression. Up-regulation of endogenous hair growth inhibi-
tors and down-regulation of endogenous hair growth pro-
moters were also observed in cultured outer root sheath 
keratinocytes upon TRPV1 activation [25]. Thus, the TRPV1 
receptor is an important regulator of human hair growth and 
its expression in hair follicles and keratinocytes suggest a 
role beyond nociception. 
Functions of TRPV1 
  Noxious stimuli are transduced by peripheral nociceptors, 
which transmit information regarding tissue damage to pain-
processing centers in the brain via the spinal cord [16].
TRPV1 in sensory nerve endings transduce various stimuli, 
in particular, inflammatory thermal pain as indicated by dele-
tion of the TRPV1 gene [30, 42]. TRPV1 is involved in both 
afferent (sensation of pain) and efferent (neurotransmitter 
and neuropeptide release) functions, which are experienced 
with a burning sensation followed by vasodilation and sweat-
ing upon consumption of capsaicin in spicy foods. Thus, 
TRPV1 can mediate both inflammation and pain and this 
dual mode of action qualifies it to be an important player in 
various physiological and pathophysiological processes. 
  Important properties of the TRPV1 receptor include sen-
sitization, desensitization and tachyphylaxis. Capsaicin, and 
certain noxious stimuli can induce a prolonged hypersensi-
tive state and capsaicin-induced hyperalgesia is a well-
characterized pain model. Following intradermal capsaicin 
injection in humans, pronounced hyperalgesia to heat and 
mechanical stimuli is experienced at the injection site, which 
later spreads to the surrounding tissue [172]. Desensitization 
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to an agonist. Tachyphylaxis is defined as a reduction in re-
sponse to repeated application of an agonist. Both desensiti-
zation and tachyphylaxis require extracellular Ca
2+ [31], 
suggesting the involvement of Ca
2+-dependent intracellular 
signaling mechanisms. Tachyphylaxis can be abolished by 
inhibitors of Ca
2+-dependent phosphatases, suggesting the 
requirement for phosphorylation in channel activation [50]. 
Thus, Ca
2+-mediated dephosphorylation may render the 
channel inactive leading to desensitization or tachyphylaxis. 
Prolonged TRPV1 activation by capsaicin may lead to its 
desensitization and this may account for the paradoxical use 
of capsaicin as an analgesic agent [171]. Interestingly, PKA-, 
but not PKC-mediated phosphorylation is able to reverse 
tachyphylaxis, suggesting distinct actions for these kinases 
[120, 121, 122]. Desensitization may result from Ca
2+-
induced modulation of TRPV1 sensitivity, and/or Ca
2+ toxic-
ity; a large and sustained Ca
2+ influx via TRPV1 has been 
linked to neurodegeneration of the peripheral nerve termi-
nals.  
ACTIVATION CHARACTERISTICS OF TRPV1 
  TRPV1 is a well-characterized channel, which transduces 
heat in the noxious temperature range (>42
oC) and is critical 
for nociceptive and inflammatory thermal sensation [80]. It 
is a Ca
2+ permeant polymodal receptor activated by protons, 
anandamide, lipoxygenase metabolites of arachidonic acid 
(AA), N-arachidonyl dopamine (NADA), capsaicin (an ac-
tive ingredient in hot chili peppers) and RTX, an ultrapotent 
agonist obtained from the cactus, Euphorbia resinifera [29]. 
RTX combines structural features of phorbol esters (potent 
activators of PKC) and vanilloid compounds. It was thought 
that its ability to activate PKC might be responsible for its 
high potency, but the concentration required to activate PKC 
is much higher to account for this effect [63]. 
  Cloning and mutational analysis of TRPV1 has improved 
our understanding of how these receptors are activated. The 
TRPV1 ion channel subunit has six transmembrane-spanning 
segments flanked by large intracellular, N- and C-terminal 
domains [31, 81, 94]. Therefore, an intracellular modulator 
or a readily membrane-permeable agent is required to acti-
vate/block the receptor. Binding of capsaicin and RTX to 
TRPV1 involves amino acid residues which have been 
shown to reside in N- and C-cytosolic and transmembrane 
domains of the channel [34, 57, 81, 82]. The binding site for 
vanilloid compounds has been reported to lie between trans-
membrane domains 2 and 4. Amino acids Y511 and S512 
may play a key role in capsaicin binding [78]. Other studies 
have implicated the importance of residues on the cytoplas-
mic tail in capsaicin and proton binding [78]. Amino acids in 
transmembrane domain 6 (N676, M677 and L678) play a 
significant role in capsaicin- and proton-induced activation 
of TRPV1 [79]. Mutation of residues at D601, E610 or E648 
to neutral or basic residues resulted in a loss of proton sensi-
tivity. In contrast, mutation of E600 resulted in increased 
sensitivity to vanilloids at higher temperatures [79].  
  A potent endogenous activator of TRPV1 has not been 
identified. Anandamide, NADA and lipoxygenase metabo-
lites of AA have been shown to activate the receptor weakly. 
However, in the phosphorylated state, agonist and tempera-
ture sensitivity is greatly increased, in that TRPV1 could be 
active at normal body temperature [130, 162, 168]. There-
fore, the activation mechanism could include multiple stim-
uli integrating synergistically to induce a maximal response.  
SENSITIZATION OF TRPV1 BY PHOSPHORYLA-
TION 
 Activation  of  Ca
2+ permeant nociceptive ion channels on 
the peripheral and central terminals of sensory neurons leads 
to the synthesis and/or release of a variety of proinflamma-
tory agents and neuropeptides, like ATP, BK, PGs, CGRP, 
SP and vasoactive intestinal peptide (VIP) [105, 114]. In-
creases in intracellular Ca
2+ initiate several second messen-
ger pathways including the activation of phospholipase A2 
(PLA2), phospholipase C (PLC) and Ca
2+-dependent kinases, 
which can lead to the generation of AA and its metabolites, 
release of Ca
2+ from intracellular stores and phosphorylation 
of nociceptive ion channels, respectively.
  TRPV1 is important in inflammatory thermal hyperalge-
sia. Recent studies have suggested that various inflammatory 
mediators are able to sensitize TRPV1 to chemical and 
physical stimuli. Inflammation results in acidic conditions, 
which can activate TRPV1 directly. The inflammatory me-
diators activate their respective G-protein coupled receptors 
to initiate secondary messenger pathways resulting in the 
activation of either PKA [20, 44, 70, 121, 131, 141], PKC 
[19, 32, 39, 130, 138, 172, 183], MAPK [76, 204], extracel-
lular Ca
2+/CaM-dependent kinase II (CaMKII) [83, 149] or 
Src kinase [77], which phosphorylate TRPV1.  
  Cyclic AMP-dependent protein kinase A (PKA) in pri-
mary afferents is important in mediating inflammatory hy-
peralgesia [144, 178, 179]. Activation of PKA by either us-
ing cAMP analogues or PGs results in hyperalgesia [178, 
179]. PKA-mediated phosphorylation of TRPV1 potentiates 
capsaicin-mediated current and increase CGRP release in 
cultured DRG neurons [64, 70, 102]. Anandamide causes 
release of neuropeptides by activating both cannabinoid 1 
(CB1) and TRPV1 receptors [5]. Activation of CB1 or CB2 
receptors has been shown to increase or decrease adenylate 
cyclase levels, which will modulate the phosphorylation state 
of TRPV1. Activation of the CB1 receptors decreases Ca
2+
and increases K
+ conductance in the presynaptic terminals 
[33] that can interfere with the action of TRPV1 distributed 
at the central terminals of sensory neurons. Phosphorylation 
at S116 in the amino terminus of TRPV1 is vital in PKA-
mediated regulation of TRPV1 desensitization [20]. Muta-
tions of S116, T370, T144, and S502 are capable of revers-
ing forskolin-induced potentiation of TRPV1 responses [20, 
121, 122, 141].  
  Phosphorylation by PKC has been shown to sensitize 
TRPV1  [32, 138]. Various algesic agents like BK, ATP, 
trypsin and PGs are known to sensitize TRPV1 by activating 
PKC downstream of their G-protein coupled receptors in 
sensory neurons and in expressed systems. PKC-dependent 
phosphorylation of TRPV1 not only potentiates capsaicin- or 
proton-evoked responses but also reduces its temperature 
threshold for activation [39, 126, 168, 183]. Serine residues 
(S502 and S800) on TRPV1 have been identified by bio-
chemical studies to be important in PKC-mediated effects 
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  Phorbol esters can sensitize TRPV1 by phosphorylating 
the channel [32, 138, 193]. They have also been reported to 
activate the channel directly as suggested by the induction of 
capsazepine-sensitive inward currents in HEK cells tran-
siently transfected with hTRPV1 [193]. PKC-mediated phos-
phorylation of TRPV1 can reduce its activation threshold by 
partially activating the receptor such that lower concentra-
tions of the agonist can fully activate the receptor [4, 138, 
193]. In addition, PKC alters the time- and voltage-
dependent properties of TRPV1. PKC-mediated phosphory-
lation of TRPV1 in DRG neuronal cultures has been shown 
to produce faster activation and slower deactivation of the 
channel [4]. Phosphorylation not only sensitizes the receptor 
and augments its response, but also promotes translocation of 
TRPV1 from the cytosol to the plasma membrane [124, 167, 
190]. 
 PKC, and PKC, calcium-independent and calcium-
dependent isoforms of PKC, respectively, have been shown 
to phosphorylate TRPV1 [29, 32, 138 193]. PKC plays a 
pivotal role in pain signaling, and the PKC gene disruption 
in mice dramatically reduces thermal and inflammatory pain 
[89]. In mice lacking PKC, acute pain was preserved, but 
the neuropathic pain was reduced [107].  
 Ca
2+ calmodulin-dependent protein kinase II (CaMKII) 
has been shown to modulate TRPV1 function and capsaicin 
binding [83, 149]. In contrast, calcineurin-mediated dephos-
phorylation causes TRPV1 desensitization [50]. Mutants of 
CaMKII phosphorylation sites on TRPV1 (S502 and T704) 
failed to elicit currents in response to application of capsaicin 
or RTX [83]. Thus, CaMKII and calcineurin control the sub-
tle balance between TRPV1 phosphorylation/dephosphory-
lation and its activation, deactivation and desensitization 
characteristics.  
  TRPV1 is activated by membrane-derived lipids like 
anandamide, oleoylethanolamide and some lipoxygenase 
products of arachidonic acid [3, 73, 205]. Phosphainositol 3, 
4 bisphosphate (PIP2) has been suggested to tonically inhibit 
TRPV1 by its constitutive association with the channel. Ac-
tivation of PLC by metabotropic receptors (BK2, TrkA and 
histamine) hydrolyzes PIP2 into diacylglycerol and inositol 
(1, 4, 5) trisphosphate, which relieves its tonic inhibition of 
the channel [35]. PIP2 regulates TRPV1 activity by interact-
ing with amino acids between 777–820, which contains 
many positively charged residues [139]. This region also 
includes S800, the PKC phosphorylation site and overlaps 
with the 35 amino acid segment necessary for CaM binding. 
This region might thus be very important for the activation 
of TRPV1. BK and histamine are coupled to PLA2, activa-
tion of which, in turn, can produce AA and its metabolites 
leading to the modulation of TRPV1 [160]. 
TRPV1 AGONISTS 
  The possibility of using TRPV1 receptor agonists to alle-
viate pain is an interesting concept. Activation of TRPV1 
can induce persistent depolarization of the nerve terminals 
causing a decrease in their ability to generate and propagate 
action potentials. On the other hand, TRPV1 activation 
causes an influx of Ca
2+ that in the long-term can cause 
nerve terminal degeneration. Ablation of TRPV1 containing 
neurons by intraperitoneal injection of capsaicin or RTX has 
been demonstrated [127, 133, 200]. Furthermore, high con-
centration of capsaicin has been used to alleviate pain asso-
ciated with herpes zoster, AIDS neuropathy, diabetic periph-
eral neuropathy, etc [80, 172]. In this strategy to avoid the 
pain caused by capsaicin, a prior application of lidocaine is 
warranted. Local application of 0.075% capsaicin ointment 
has been reported to have moderate to poor efficacy follow-
ing eight weeks of application in neuropathic or muscu-
loskeletal pain [113]. In itch-causing pruritis, capsaicin 
0.006% has been found to be useful [104].  
  Intrathecal administration of capsaicin has been shown to 
cause a long-lasting loss of thermal sensitivity without af-
fecting mechanical sensitivity [200]. RTX is a potent agonist 
of TRPV1, which exhibits unique properties that can be ex-
ploited to treat chronic pain conditions [140]. The character-
istics of RTX include the following: 1. irreversible nature of 
activation enables the use of low concentrations (well below 
the toxic levels); 2. slow and sustained depolarization results 
in a gradual inactivation of voltage-gated Na
+ channels caus-
ing a depolarization block, preventing action potential gen-
eration in the short-term and Ca
2+-induced nerve terminal 
death in the long-term [140]. Since the nerve terminals have 
the ability to regenerate, long-term toxicity may not be a 
major concern. Intrathecal administration of RTX causes a 
loss of thermal sensitivity [175]. Idalora and colleagues [27] 
have used intrathecal administration of RTX to alleviate pain 
associated with osteosarcoma in dogs. We have found that 
selective ablation of central terminals of DRG neurons by 
intrathecal administration of RTX can achieve reduction of 
nociceptive neurotransmission. RTX in very low (nanomo-
lar) concentrations can activate TRPV1 slowly, maximally 
and irreversibly leading to depolarization beyond the thresh-
old without generating action potentials. RTX-induced sus-
tained depolarization leads to the loss of generation of action 
potentials in the peripheral and/or central TRPV1 containing 
nociceptor nerve terminals in the short-term and ablation of 
these nerve terminals in the long-term. This has the potential 
to alleviate chronic pain conditions (S.Y. and L.S.P., unpub-
lished results). The prevention of permanent loss of the DRG 
is therapeutically favorable and offers a unique approach to 
treat chronic pain conditions. The selectivity of RTX action 
on TRPV1-containing nociceptive nerve terminals may offer 
an advantage of a higher therapeutic index compared to other 
clinically available agents (toxins), such as, botulinum toxin 
and -conopeptide, which act on synaptic vesicles and on 
Ca
2+ channels, respectively. 
TRPV1 ANTAGONISTS 
  For decades the only antagonist available to inhibit cap-
saicin-mediated responses was the organo-metallic dye ru-
thenium red [53]. Ruthenium red is a non-competitive an-
tagonist of TRPV1; however, based on recent studies it can 
be classified as a general inhibitor of TRPV channels [60, 
164]. The mechanism of action is proposed to be by blocking 
the channel pore. Moreover, it has also been demonstrated to 
block other channels, in particular Ca
2+ channels [53]. The 
well-studied TRPV1 antagonist is the synthetic vanilloid 
analogue, capsazepine [18, 187]. Capsazepine is a competi-
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and in vitro effects of capsaicin and exhibits a relatively high 
selectivity for TRPV1 as compared to other TRPV channels. 
However, capsazepine is far from being an ideal TRPV1 
antagonist as it has many disadvantages. First, it is a very 
weak antagonist with IC50 values of 0.2-4 IM [2, 18, 31, 
101, 188, 199]. Second, it demonstrates species-dependent 
difference in inhibiting TRPV1. Capsazepine inhibits acid-
induced activation of human TRPV1 (hTRPV1), but has no 
inhibitory effect on acid-induced activation of rat TRPV1 
(rTRPV1) [190]; however, it can inhibit heat-mediated re-
sponses in both hTRPV1 and rTRPV1. Third, at concentra-
tions needed to inhibit TRPV1 (~10 IM), it has been demon-
strated to block amongst many receptors and channels, volt-
age-gated calcium channels [51] and acetylcholine receptors 
[101]. Furthermore, the sarcoplasmic reticulum ATPase 
(SERCA) inhibitor, thapsigargin, was shown to inhibit the 
capsaicin-induced calcium influx with an IC50 of 6.4 ± 1.9 
IM as well as prevented [
3H] RTX binding (IC50 = 4 ± 1.3 
IM) in CHO cells expressing TRPV1 [186]. 
  Iodination of RTX at the 5 position of the vanilloid moi-
ety resulted in one of the most potent TRPV1 antagonist 
iodo-resiniferatoxin (iodo-RTX) [196]. Iodo-RTX has been 
reported to inhibit capsaicin-induced currents in Xenopus 
laevis oocytes expressing TRPV1 with an IC50 value of 3.9 
nM. Intrathecal administration inhibited capsaicin-elicited 
pain responses with ED50 of 16 ng/mouse [196]. Further-
more, iodo-RTX has been demonstrated to inhibit both heat- 
and proton-evoked responses in sensory neurons as well as 
cells expressing the recombinant TRPV1 [145]. However, in 
an interesting study by Shimizu and colleagues [159], sys-
temic administration of iodo-RTX in mice resulted in hypo-
thermia, as these effects were not seen in either TRPV1 
knock-out mice or RTX-pretreated animals. Iodo-RTX was 
also shown to enhance intracellular calcium levels and in-
duced a small inward current in HEK293 cells stably trans-
fected with TRPV1. A possible suggested explanation for the 
partial agonistic action of iodo-RTX is that it is metabolized 
(deiodination) to RTX in vivo. The controversy over the an-
tagonistic vs. partial agonistic action of iodo-RTX has re-
sulted in a loss of enthusiasm over this compound. 
  Since TRPV1 has become an undisputed target for a va-
riety of painful conditions, a quest for synthesizing potent 
yet selective TRPV1 antagonists is unabated. A non-
vanilloid TRPV1-antagonist N-(4-tertiarybutylphenyl)-4-(3-
chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide 
(BCTC) has been synthesized. It inhibits capsaicin- and acid-
induced responses in rat TRPV1 with an IC50 value in the 
range of 6-35 nM; unlike capsazepine, however, BCTC does 
block acid-mediated activation of rat TRPV1 [190]. Fur-
thermore, orally administered BCTC (3-30 mg/kg) has also 
been demonstrated to inhibit both mechanical and thermal 
hyperalgesia associated with complete Freund’s adjuvant-
induced inflammation and nerve injury [137] without affect-
ing normal/acute nociception. BCTC is lipophilic and 
crosses the blood-brain barrier and may carry the risk of in-
ducing central nervous system side effects. However, in its 
analgesic concentrations, BCTC has not been documented to 
produce any locomotor impairment usually associated with 
centrally acting analgesics.
  The Glaxo Smith Kline compound SB-366791 is a com-
petitive inhibitor of TRPV1 that inhibits capsaicin, acid and 
noxious heat-mediated activation of the receptor. It is supe-
rior to capsazepine as it blocks acid-mediated activation of 
rTRPV1. It has demonstrated a high selectivity in 47 differ-
ent binding and electrophysiological assays [61]. Further-
more, SB-366791 does not inhibit VGCC or hyperpolariza-
tion-activated current (Ih) in cultured rodent sensory neurons. 
In a recent study, spontaneous and miniature excitatory syn-
aptic currents (sEPSC and mEPSC), recorded from the sub-
stantia gelatinosa neurons of the spinal cords obtained from 
CFA-injected animals, were decreased in the presence of SB-
366791 [96]. 
  Abbott laboratories have in the recent years synthesized a 
number of promising TRPV1 antagonists. The A-425619 [1-
Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea] is a com-
petitive, potent (IC50= 5-9 nM) and a highly selective an-
tagonist for the capsaicin receptor [54]. It inhibits increases 
in intracellular calcium influx evoked by capsaicin, NADA, 
anandamide or pH in HEK cells transfected with hTRPV1 as 
well as capsaicin-induced inward currents in cultured rat 
DRG neurons. Furthermore, in experiments, where TRPV1 
receptors expressed in HEK cells were sensitized by a PKC 
activator, PDBu or low pH 6.0, capsaicin-mediated intracel-
lular influx was inhibited by A-425619 at much lower con-
centrations (pA2 = 0.8 ± 0.3 and 4.3 ± 1.9 nM, respectively). 
Recently, a detailed study highlights the properties of two of 
their leading contenders for antagonizing TRPV1 receptor 
that are orally active. A-784168 (1-[3-(trifluoromethyl)pyri-
dine-2-yl]-N-[4-(trifluoromethylsulfonyl)phenyl]-1,2,3,6-tet-
rahydropyridine-4-carboxamide) and A-795614 (N-1H-
indazol-4-yl-N’- [(1R)-5-piperidin-1-yl-2,3-dihydro-1H-inden-
1-yl]urea) have comparable efficacy in in-vitro assays (IC50=
25 ± 2 and 14 ± 1 nM, respectively, in inhibiting capsaicin-
mediated responses), but have significant differences in their 
ability to permeate the CNS [38]. Interestingly, in models 
representing chronic pain conditions, including CFA- and 
capsaicin-induced mechanical allodynia and osteoarthritis, 
both agents demonstrated equal efficacy when administered 
intrathecally; however, when administered orally, A-784168, 
which crosses the blood-brain barrier, was found to be supe-
rior than A-795614 [38]. This study clearly demonstrates that 
drugs which cross the blood-brain barrier are more efficient 
in antagonizing TRPV1 in vivo. However, it could also be 
argued that such highly lipophilic compounds may be asso-
ciated with a greater CNS side effect profile, because of 
TRPV1 distribution in the brain.  
  Amgen has developed a piperazinylpyrimidine analog 
(AMG517) as a potent TRPV1 antagonist, which is in the 
phase 1 clinical trials. Amgen has also developed other po-
tent compounds (AMG0347, AMG8163, AMG9810), IC50
values to antagonize capsaicin responses range between 0.5 
to 86 nM [173]. Neurogen/Merck has launched NDG-
8243/MK-2295 in Phase II clinical trials, the structure of 
which is unpublished/unreported. The latest compound to 
enter clinical trials is GRC-6211 from Glenmark pharmaceu-
ticals. Other TRPV1 antagonists include JNJ-17203212 
(Johnson and Johnson) has been shown to be effective in 
bone cancer pain and JYL1421 (Schwarz Pharma), which 158    Current Neuropharmacology, 2008, Vol. 6, No. 2 Premkumar and Sikand 
blocks capsaicin induced responses with an IC50 of 9.2 M
[173]. 
  The NGF antibody is being evaluated for the treatment of 
chronic pain. NGF has been shown to sensitize TRPV1 by 
activating PLC and hydrolyzes PIP2, which tonically inhibits 
the channel [35, 139], or by activating PKC, PI3K [26, 35, 
161, 167] and ERK [204]. Although the precise mechanism 
of action is debatable, it is known that NGF sensitizes 
TRPV1 and increases its expression and function. Therefore, 
blocking NGF action could down regulate TRPV1 expres-
sion and function.  
CONCERNS OF TRPV1 ANTAGONISTS 
TRPV1 antagonists hold a great promise in alleviating 
multiple modalities of pain. However, it must be borne in 
mind that other physiological functions that are mediated by 
TRPV1 channels may be affected. Of concern are the main-
tenance of body temperature, TRPV1-mediated SP and 
CGRP release and their subsequent effect on the cardiovas-
cular functions and acute nociception. Particular efforts 
should be focused on changes in body temperature. In some 
studies, the body temperature has been shown to rise as 
much as 3
oC. Cardiovascular consequences range from the 
inability to feel pain during myocardial ischemia to de-
creased TRPV1-mediated CGRP release that can compro-
mise coronary circulation. CGRP is also critical for the in-
tegrity of microvascular circulation and lack of which could 
aggravate diabetic peripheral neuropathy and peripheral vas-
cular disease. Gastrointestinal consequences could occur as a 
result of a decreased release of neuroactive substances, as 
well as by modulation of vagal nerve circuitry. The preferred 
route of oral administration of TRPV1 antagonists could 
have an immediate impact on the gastrointestinal functions. 
The main disadvantage with the existing nonselective COX 
inhibitors is that they increase gastric acid section that may 
lead to life threatening bleeding due to decreased PG synthe-
sis. However, studies have suggested that capsaicin is capa-
ble of releasing HCO3
- as efficiently as acid challenge. 
Therefore, blocking TRPV1 may decrease the release of 
HCO3
-, which is essential to neutralize the acid. Recent stud-
ies show that the TRPV1 knock-out animals have deficien-
cies in fear conditioning and memory formation, which are 
serious issues to consider. RTX is in clinical trials for the 
treatment of urinary bladder hyperreflexia. Therefore, it 
should be evaluated how the block of TRPV1 could affect 
normal bladder functions. Furthermore, blocking TRPV1 has 
been shown to increase its own expression, thereby raising 
the possibility of rebound effects. Given the observations 
that TRPV1 knock-out mice have normal life span without 
serious abnormalities, suggest that the block of TRPV1 may 
not induce serious adverse effects. However, it has to be in-
vestigated how these animals react upon insult or in patho-
logical conditions. 
CONCLUDING REMARKS 
  Although, TRPV1 is considered to be a potential target 
for developing drugs to treat different modalities of pain, 
extensive basic science research and clinical trials have to be 
undertaken to uncover possible adverse effects. This task is 
further complicated by the advent of TRPV1 distribution in 
novel areas mediating unexpected functions. In particular, 
antagonizing the receptor may lead to cardiovascular com-
plications as a result of decreased vasoactive peptide release. 
Sustained stimulation can also lead to Ca
2+-dependent nerve 
terminal degeneration. Therefore, the consequence could be 
as a result of both agonistic and antagonistic actions. Finally, 
there is no drug that has been invented without adverse ef-
fects; therefore, the balance between the beneficial and the 
adverse effects should be cautiously and pragmatically con-
sidered. Using agents to selectively target nerve terminals at 
the periphery or at the level of the spinal cord may avoid 
some of the systemic adverse effects. In any case, TRPV1 is 
a novel target for next generation analgesics, and if proven to 
be successful in clinical trials, its agonists and antagonists 
may be added to the therapeutic armamentarium.  
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